NCT04047732View on ClinicalTrials.gov

Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

October 31, 2022

Study Completion Date

March 31, 2025

Conditions
TGM-1 Related Autosomal Recessive Congenital Ichthyosis
Interventions
BIOLOGICAL

KB105

KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel

Trial Locations (2)

19103

Paddington Testing Company, Inc., Philadelphia

60611

Northwestern University, Chicago

Sponsors
All Listed Sponsors
lead

Krystal Biotech, Inc.

INDUSTRY

NCT04047732 - Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | Biotech Hunter | Biotech Hunter